title: Late hemorrhagic cystitis after reduced-intensity hematopoietic stem cell transplantation (RIST).
abstract: We reviewed medical records of 256 patients to investigate the frequency and characteristics of hemorrhagic cystitis (HC) associated with reduced-intensity stem cell transplantation (RIST) as opposed to conventional stem cell transplantation (CST); 137 patients underwent CST and 119 RIST. Diagnosis of HC was made based on two or more episodes of sterile, macroscopic hematuria with normal coagulation profiles, without any evidence of renal stones or genitourinary malignancy. Actuarial frequency of HC development in RIST group was 7.6% (9/119), which gave a cumulative annual incidence of 11.7%. In CST group, 13 of 137 patients (9.5%) developed HC, giving an estimated annual incidence of 9.7%. The probability of developing HC was similar between the two groups (P=0.77). The viral etiologies of HC, adenovirus (n=12) and BK virus (n=2), were documented in eight patients after RIST and in six after CST. HC was milder and of a shorter duration, with less blood transfusion requirements, in RIST group than in CST group. A multivariate analysis revealed that HC was associated with antiadenovirus antibody positivity in the recipients, total dose of busulfan, and chronic GVHD. Although HC following RIST is less severe than that following CST, it is still a significant problem.
authors: Hematopoietic Stem Cell Transplantation Unit, National Cancer Center Hospital, Tokyo, Japan.
authors: R
authors: R
authors: Yamamoto
authors: E
authors: E
authors: Kusumi
authors: M
authors: M
authors: Kami
authors: K
authors: K
authors: Yuji
authors: T
authors: T
authors: Hamaki
authors: A
authors: A
authors: Saito
authors: N
authors: N
authors: Murasgihe
authors: A
authors: A
authors: Hori
authors: S-W
authors: SW
authors: Kim
authors: A
authors: A
authors: Makimoto
authors: J
authors: J
authors: Ueyama
authors: R
authors: R
authors: Tanosaki
authors: S
authors: S
authors: Miyakoshi
authors: S
authors: S
authors: Mori
authors: S
authors: S
authors: Morinaga
authors: Y
authors: Y
authors: Heike
authors: S
authors: S
authors: Taniguchi
authors: S
authors: S
authors: Masuo
authors: Y
authors: Y
authors: Takaue
authors: Y
authors: Y
authors: Mutou
mesh_terms: D000256:Adenoviridae / Q000276:immunology; D000293:Adolescent; D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood; D002066:Busulfan / Q000008:administration & dosage / Q000633:toxicity; D002648:Child; D002675:Child, Preschool; D003556:Cystitis / Q000139:chemically induced / Q000209:etiology* / Q000821:virology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006086:Graft vs Host Disease / Q000150:complications; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods; D006474:Hemorrhagic Disorders / Q000139:chemically induced / Q000209:etiology / Q000821:virology; D006801:Humans; D015994:Incidence; D007223:Infant; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors
chemical_list: D000914:Antibodies, Viral; D002066:Busulfan